Stockreport

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF CAMBRIDGE, Mass. Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel [Read more]